SALT
LAKE CITY, March 13, 2025 /PRNewswire/ --
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics
company with a unique, patented platform for the development of
molecular diagnostic tests, announced today it will release its
fourth quarter and full year 2024 results on Thursday, March 27, 2025, after the market close.
The Company will also host a conference call and webcast on the
same day at 4:30 p.m. ET to discuss
its financial results with analysts. Management on the call
will include Dwight Egan, Chief
Executive Officer, Brian Brown,
Chief Financial Officer, and Andrew
Benson, Head of Investor Relations.
The conference call and webcast will be available via:
Webcast: ir.codiagnostics.com on the Events
& Webcasts page
Conference Call: 844-481-2661 (domestic) or
412-317-0652 (international)
If you are unable to participate during the live webcast, the
call will be recorded and later made available on the Company's
website.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR at-home and point-of-care platform and to
identify genetic markers for use in applications other than
infectious disease.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-announces-fourth-quarter-and-full-year-2024-earnings-release-date-and-webcast-302400872.html
SOURCE Co-Diagnostics
